Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

2seventy/BMS Halt Abecma Maintenance Trial As Landscape Evolves

Sep 25 2024

• By Alaric DeArment

• Source: Shutterstock

Related Content

2Seventy Cuts Jobs As It Streamlines Pipeline, Focuses On Abecma

Sep 12 2023

Bluebird Spinoff 2seventy Bio Gets Its Own Wings

Oct 19 2021

BMS’s Abecma Shakes Up Myeloma With Earlier-Line Approval From FDA

Apr 05 2024

BMS ‘Increasingly Confident’ It Can Handle The Impact Of Medicare Pricing For Eliquis

Jul 26 2024

J&J’s Spravato On Track To Be A Blockbuster, Five Years In

Jul 17 2024

J&J’s Carvykti Claims Broadest CAR-T Label In Multiple Myeloma

Apr 08 2024

Abecma Or Bust: 2seventy Sells Final Research Program To Novo

Jun 27 2024

It’s All About Abecma As 2seventy Sells Off Pipeline To Regeneron In Restructuring

Jan 30 2024

Related Companies

2seventy Bio, Inc.

Johnson & Johnson

Legend Biotech Corp.

Genetix Biotherapeutics

Regeneron Pharmaceuticals, Inc.

Additional Topics

Clinical Trials Business Strategies Research & Development CAR-T BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window